40 registrations that name cannabidiol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 40 registrations
Status
Phase
38US sites across 16 states
1
2 to 4
5 to 19
20 or more
All 40 registrations
RecruitingNCT06940674
Adjunctive Cannabidiol for Recovery From Opioid Study
Phase 3
Icahn School of Medicine at Mount Sinai
About 450 people
Started Jun 13, 2025
In plain words A Phase 3 study of cannabidiol in people 18 to 65, run by Icahn School of Medicine at Mount Sinai. It plans to enroll about 450 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Opioid Use Disorder (OUD).
Individuals between 18 and 65 years old.
Ability to understand and give informed consent.
Current opioid use disorder (OUD) or OUD in remission while on maintenance therapy with OAT, as determined by DSM-5 with the M.I.N.I. interview (Mini-International Neuropsychiatric Interview).
Current opioid agonist maintenance treatment with methadone or buprenorphine for at least 14 days prior to consent. With the following more specific criteria for each of these two medications:
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of CBD (BSPG CBD; Brains Bioceutical). The second phase was a double-blinded randomized controlled trial to determine whether CBD reduces craving and anxiety in individuals with OUD maintained on opioid agonist therapy. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT06234631
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
Phase 2
Chad Brummett
About 380 people
Started Mar 13, 2024
In plain words A Phase 2 study of cannabidiol in people 18 to 80, run by Chad Brummett. It plans to enroll about 380 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Knee Replacement Surgery; Osteoarthritis, Knee.
Willing and able to read, understand, and sign the informed consent (English)
Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up
Scheduled for surgery: primary total knee arthroplasty
Primary diagnosis of osteoarthritis of the surgical knee
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Epidiolex oral solution; Placebo
Registered summary
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Where, as registered
2 US sites in 1 state.
RecruitingNCT04411225
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Phase 3
University of California, San Diego
About 120 people
Started Jun 1, 2022
In plain words A Phase 3 study of cannabidiol in people 16 to 30, run by University of California, San Diego. It plans to enroll about 120 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 30. Conditions: Early Psychosis.
First episode psychosis (onset within the last 2 years) or attenuated psychosis syndrome (APS), stabilized with treatment for at least 8 weeks prior to initiating the trial consistent with the FDA-NIMH-MATRICS guidelines for clinical trial…
Clinically stable and in a nonacute phase of their illness for at least 2 months, First episode psychosis participants will have been maintained on current antipsychotic for at least 6 weeks, with no change in antipsychotic dose for the…
Exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤ 4) on PANSS items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior), P5 (grandiosity), P6 (suspiciousness), and G8 (unusual…
No more than a minimal level of depressive symptoms as assessed by the Calgary Depression Scale for Schizophrenia (CDSS)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol oral solution
Registered summary
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.
Where, as registered
2 US sites in 1 state.
RecruitingNCT06731894
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Phase 2
City of Hope Medical Center
About 120 people
Started Oct 3, 2025
In plain words A Phase 2 study of cannabidiol in people 18 and older, run by City of Hope Medical Center. It plans to enroll about 120 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Breast Carcinoma; Chemotherapy-Induced Peripheral Neuropathy; Colon Carcinoma.
Documented informed consent of the participant and/or legally authorized representative.
Assent, when appropriate, will be obtained per institutional guidelines
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
If unavailable, exceptions may be granted with study principal investigator (PI) approval
12 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. The full summary is on the listing.
Where, as registered
2 US sites in 1 state.
RecruitingNCT06381180
Warrior CARE: Cannabis Behavioral Health
Phase 1 and 2
Wayne State University
About 500 people
Started Sep 22, 2025
In plain words A Phase 1 and 2 study of cannabidiol in people 19 to 69, run by Wayne State University. It plans to enroll about 500 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 69. Conditions: Post Traumatic Stress Disorder; Cannabis Use; Suicide; Veterans; Marijuana.
a healthy veteran who has served in a branch of the US armed forces
report using cannabis within the past year
currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service)
between the ages of 19-69 years old
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Tetrahydrocannabinol; Cannabidiol; Placebo
Registered summary
This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.
Where, as registered
1 US site in 1 state.
RecruitingNCT06213233
MIVetsCan: Cannabidiol (CBD)-Care Trial
Phase 2
Kevin Boehnke
About 468 people
Started Feb 12, 2024
In plain words A Phase 2 study of cannabidiol in people 18 and older, run by Kevin Boehnke. It plans to enroll about 468 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pain, Chronic.
Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
Armed Services Veteran
All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
Reports moderate to severe chronic pain defined by protocol
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Cannabidiol
Registered summary
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period. The study hypotheses: \- CBD would improve overall pain symptoms compared to placebo
Where, as registered
1 US site in 1 state.
RecruitingNCT06686914
The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
Phase 1
West Virginia University
About 300 people
Started Jun 30, 2025
In plain words A Phase 1 study of cannabidiol in people 18 to 30, run by West Virginia University. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Cannabidiol Effects; Driving Performance.
Possess a current drivers' license
Driven a motor vehicle at least once in the past 30 days
Able to read English
Test negative for all substances on a urine drug test and complete a test drive to ensure the absence of simulation sickness
3 more inclusion criteria and the exclusion criteria are on the listing.
The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.
Where, as registered
1 US site in 1 state.
RecruitingNCT05822362
CBD for Individuals at Risk for Alzheimer's Disease
Phase 2
University of Colorado, Denver
About 236 people
Started Jan 19, 2024
In plain words A Phase 2 study of cannabidiol in people 55 to 85, run by University of Colorado, Denver. It plans to enroll about 236 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 85. Conditions: Mild Cognitive Impairment.
Must be between the ages of 55 - 85 and provide valid informed consent.
Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician, or have symptoms of Mild Cognitive Impairment as determined by the study physician.
Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently.
Montreal Cognitive Assessment (MoCa) score is ≤ 25
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.
Where, as registered
1 US site in 1 state.
RecruitingNCT04992624
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
Phase 2
Steven E Harte, PhD
About 200 people
Started Feb 22, 2022
In plain words A Phase 2 study of cannabidiol in people 21 to 75, run by Steven E Harte, PhD. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 75. Conditions: Osteoarthritis, Knee; Osteoarthritis of the Knee.
Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures
Willingness to participate in a drug intervention trial
Diagnosis of osteoarthritis (OA) of the knee by a medical provider (confirmed by checking medical records)
Chronic knee pain, defined as moderate to severe knee pain for ≥ 6-month duration
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Cannabidiol (CBD); Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Registered summary
This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms. Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05613608
Alcohol Use Disorder and Cannabidiol
Phase 2 and 3
University of Colorado, Denver
About 180 people
Started Apr 30, 2023
In plain words A Phase 2 and 3 study of cannabidiol in people 21 and older, run by University of Colorado, Denver. It plans to enroll about 180 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 and older. Conditions: Alcohol Use Disorder.
Must be ≥21 years old.
Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria for current Alcohol Use Disorder (AUD) of at least moderate severity (i.e., 4 or more DSM-V symptoms).
Expresses desire to reduce or quit drinking.
If male, reports drinking, on average, at least 15 standard alcoholic drinks per week prior to screening; if female, reports drinking, on average, at least 10 standard drinks per week prior to screening, or if a male respondent reports…
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
Where, as registered
1 US site in 1 state.
RecruitingNCT05269628
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Phase 2
Tiffany J. Braley, MD, MS
About 166 people
Started Mar 25, 2022
In plain words A Phase 2 study of cannabidiol in people 18 to 65, run by Tiffany J. Braley, MD, MS. It plans to enroll about 166 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Multiple Sclerosis; Sleep; Pain.
Patients with clinically definite MS (those who are on a disease modifying therapy must be on a stable dose without evidence of liver toxicity for at least 3 months);
Presence of chronic pain defined as moderate to severe pain for at least 3 months, based on a 0-10 numeric rating scale (NRS);
Willingness to maintain stable analgesic regimen during study period;
Recent serum aspartate transaminase, alanine transaminase, and bilirubin testing within 90 days of screening;
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
Where, as registered
1 US site in 1 state.
RecruitingNCT06107062
Longitudinal Outpatient Treatment for Cannabis Use Disorder
Phase 2
University of Colorado, Boulder
About 165 people
Started Jul 26, 2024
In plain words A Phase 2 study of cannabidiol in people 21 and older, run by University of Colorado, Boulder. It plans to enroll about 165 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 and older. Conditions: Cannabis Use Disorder.
Regular use (at least 4 times per week) of cannabis concentrates for at least the last year.
Meets DSM5 criteria for at least moderate CUD.
Currently seeking to cut down or stop cannabis use.
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol - fsCBD; Placebo; Cannabidiol - bsCBD
Registered summary
This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy treatment for CUD. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05283382
Cannabidiol Effects on Learning and Anxiety
Early phase 1
University of Connecticut
About 160 people
Started Oct 30, 2024
In plain words An early phase 1 study of cannabidiol in people 18 to 50, run by University of Connecticut. It plans to enroll about 160 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50; healthy volunteers accepted. Conditions: Anxiety and Fear.
18-50 years of age
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol Oral Product; Placebo
Registered summary
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07278505
Study of Cannabidiol and Neuroimaging on Stress
Phase 1 and 2
Icahn School of Medicine at Mount Sinai
About 160 people
Started Oct 29, 2025
In plain words A Phase 1 and 2 study of cannabidiol in people 18 to 25, run by Icahn School of Medicine at Mount Sinai. It plans to enroll about 160 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 25; healthy volunteers accepted. Conditions: Early Life Adversity; Trauma; Stress.
Ability to understand and give informed consent.
Individuals between 18 and 25 years old; Sex is used a biological factor (50% of individuals recruited will be females, allowing sex comparisons).
English speakers.
Cognitive performance at threshold of greater than or equal to 23 as assessed by the Montreal Cognitive Assessment (MoCA).
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05885542
SCORE Emerging Adult Cannabis Use & Stress
Phase 1 and 2
Medical University of South Carolina
About 148 people
Started Nov 1, 2023
In plain words A Phase 1 and 2 study of cannabidiol in people 18 to 25, run by Medical University of South Carolina. It plans to enroll about 148 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 25. Conditions: Cannabis Use Disorder.
Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments
Meet DSM-5 criteria for CUD and report using cannabis at least five times weekly over the past month. While individuals may also meet criteria for other mild substance use disorders, they must identify cannabis as their primary substance
Age 18-25
BMI between 18-30 (to decrease variability in CBD response and in endocannabinoid system measures)
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol oral solution; Placebo
Registered summary
The interface between cannabis use and stress is a particularly important focus for sex differences research in emerging adults. Given the dynamics at play in this critical stage when cannabis use is most prevalent, developmentally informed research is needed to guide tailored clinical interventions. This study will apply rigorous and innovative methods to elucidate sex differences in the nexus of cannabis use and stress among emerging adults with cannabis use disorder to guide the development of tailored treatments.
Where, as registered
1 US site in 1 state.
RecruitingNCT05269459
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
Phase 2
University of Nebraska
About 140 people
Started Dec 1, 2022
In plain words A Phase 2 study of cannabidiol in people 21 to 65, run by University of Nebraska. It plans to enroll about 140 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 65. Conditions: PTSD.
Ability and willingness to provide informed consent
Stated willingness to comply with all study procedures and availability for duration of the study
Aged 21-65 years
Able to read and communicate in English
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol Administered as Nantheia ATL5; Placebo
Registered summary
Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half of US adults experience trauma in their lifetime, most do not develop PTSD. However, those who do develop the disorder may have significant impairments and risk for functional dysfunction across multiple domains. While short term symptoms are the most common, some individuals develop chronic PTSD. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04550377
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
Phase 2
NYU Langone Health
About 120 people
Started May 26, 2021
In plain words A Phase 2 study of cannabidiol in people 18 to 70, run by NYU Langone Health. It plans to enroll about 120 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Post Traumatic Stress Disorder; Traumatic Brain Injury.
Meets clinical criteria for Posttraumatic Stress Disorder (PTSD) as per Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
TBI present (for PTSD+TBI subjects only) as per American Congress of Rehabilitation Medicine (ACRM) definition
Mild TBI (for PTSD+TBI subjects only) as per Ohio State University Identification Screener
Able to provide at least 2 locators
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
This will be a randomized placebo controlled study to test the efficacy of cannabidiol (CBD) as a treatment for symptoms of post-traumatic stress disorder (PTSD). Subjects, 120 in total, will be males and females with PTSD, half of which will have comorbid mild traumatic brain injury (TBI). There will be three study arms, each with 40 subjects: 1) Oral CBD 400 mg daily; 2) Oral CBD 800 mg daily, and 3) Placebo daily. Treatment duration will be 8 weeks. The primary outcome will be change in PTSD symptoms as measured by change in the Clinician-Administered PTSD Scale (CAPS-5) total score.
Where, as registered
1 US site in 1 state.
RecruitingNCT06218056
Cannabidiol for Reducing Cigarette Use
Phase 2
University of California, Los Angeles
About 120 people
Started Oct 31, 2024
In plain words A Phase 2 study of cannabidiol in people 18 to 65, run by University of California, Los Angeles. It plans to enroll about 120 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Tobacco Use Disorder; Tobacco Smoking; Tobacco Dependence.
What it tests, as registered
Cannabidiol (CBD) 800 mg; Placebo
Registered summary
The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07148843
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Phase 2 and 3
Johns Hopkins University
About 105 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 2 and 3 study of cannabidiol in people 21 to 65, run by Johns Hopkins University. It plans to enroll about 105 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 65. Conditions: Alcohol Use Disorder (AUD); Withdrawal From Addictive Substance; Detoxification; Craving.
Meets DSM-5 criteria Moderate or Severe Alcohol Use Disorder
Age 21-65
Report at least one prior episode of alcohol withdrawal symptoms at least one day in duration that caused significant impairment in functioning (i.e., unable to attend work or engage in typical activities) AND/OR required medications to…
Report at least 21 days of heavy drinking (four or more drinks for women, five or more drinks for men) over the last 28 days.
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol (CBD); Placebo
Registered summary
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05020028
Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
Phase 2 and 3
NYU Langone Health
About 100 people
Started Jun 22, 2022
In plain words A Phase 2 and 3 study of cannabidiol in people 40 to 75, run by NYU Langone Health. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75. Conditions: Knee Arthritis.
Patients presenting with knee osteoarthritis (KL Grade II-III)
Knee pain for at least three months, occurring in at least half of the days in that period
VAS ≥ 4
Patients ages 40-75, inclusive
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol (CBD); Placebo
Registered summary
The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.
Where, as registered
1 US site in 1 state.
RecruitingNCT07001930
Effects of Cannabidiol on Stress and Nicotine Withdrawal
Phase 1
Johns Hopkins University
About 90 people
Started Aug 25, 2025
In plain words A Phase 1 study of cannabidiol in people 21 to 70, run by Johns Hopkins University. It plans to enroll about 90 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 70. Conditions: CBD; Stress; Nicotine Dependence; Tobacco Smoking.
Use of > 5 cigarettes per day for > 2 years. (Use of other tobacco/nicotine products in addition to cigarettes will be acceptable).
Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level >= 5 ppm.
Alcohol Use: < 2 drinks/day on average (< 14 drinks/week).
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Epidiolex
Registered summary
The purpose of this study is to examine the effect of doses of cannabidiol (CBD) during exposure to stress and nicotine withdrawal in nicotine users. The main objectives of the study include examining the effect CBD has on stress, tobacco dependence, tobacco withdrawal, and sex differences between these types of stress. Participants will be administered CBD and exposed to stress. Biological and subjective measures will be collected. Participants may be asked to stop use for 24 hours. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06381791
CBD for Pain Following Orthopedic Shoulder Surgery
Phase 1 and 2
The Methodist Hospital Research Institute
About 80 people
Started May 24, 2024
In plain words A Phase 1 and 2 study of cannabidiol in people 18 and older, run by The Methodist Hospital Research Institute. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Shoulder Osteoarthritis; Rotator Cuff Injuries.
Above the age of 18 years old
Undergoing a rotator cuff repair surgery
Receiving standard anesthesia during surgery
If a subject is of reproductive potential, they must be on effective contraception one month prior, during treatment, and one month following treatment.
The exclusion criteria are on the listing.
What it tests, as registered
Epidiolex; Placebo oral solution
Registered summary
The goal of the study is to learn if Epidiolex (cannabidiol) works as a additional pain medication in patients who have had orthopedic shoulder surgery. It is also to learn about safe dosages and identify any side effects after surgery. Researchers will compare Epidiolex to a placebo solution to see if Epidiolex lowers pain after shoulder surgery. Participants will: * track their pain and what medications they use every day in a provided pain diary. A researchers will call every seven days to check on the participant and diary. * Complete two short surveys. Once before surgery and once after. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06930703
Cannabidiol in Sickle Cell Disease
Phase 1 and 2
Icahn School of Medicine at Mount Sinai
About 52 people
Started Apr 3, 2025
In plain words A Phase 1 and 2 study of cannabidiol in people 18 and older, run by Icahn School of Medicine at Mount Sinai. It plans to enroll about 52 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sickle Cell Disease.
Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain
If on a SCD modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab), on stable dose for at least 3 months
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.
Where, as registered
1 US site in 1 state.
RecruitingNCT05649059
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
Phase 4
Massachusetts Institute of Technology
About 50 people
Started Jul 10, 2025
In plain words A Phase 4 study of cannabidiol in people 18 to 55, run by Massachusetts Institute of Technology. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 55. Conditions: Phobia, Social.
Ability and willingness to provide written informed consent.
Sufficiently fluent in English to participate in the trial.
Between 18-55 years of age (inclusive).
Right-hand dominant.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Where, as registered
1 US site in 1 state.
RecruitingNCT06113237
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
Observational
Jazz Pharmaceuticals
About 50 people
Started Aug 5, 2025
In plain words An observational study of cannabidiol in female participants of any age, run by Jazz Pharmaceuticals. It plans to enroll about 50 people at 3 sites, 1 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants of any age. Conditions: Maternal Complications; Pregnancy Complication; Birth Outcomes, Adverse; Pregnancy.
Patients with exposure to at least 1 dose of Epidiolex/Epidyolex during the 13 days prior to their LMP or at any time during pregnancy.
Verbal or written informed consent to participate
The exclusion criteria are on the listing.
What it tests, as registered
Epidiolex
Registered summary
The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
Where, as registered
1 US site in 1 state; also Germany (1), Italy (1).
RecruitingNCT05015439
Cannabidiol (CBD) in Adults With ASD
Phase 1
Johns Hopkins University
About 40 people
Started Apr 20, 2023
In plain words A Phase 1 study of cannabidiol in people 18 and older, run by Johns Hopkins University. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Autism Spectrum Disorder.
ASD based on Diagnostic Statistical Manual 5 (DSM-5) criteria
a significant mood disorder, sleep disturbance, or exhibit agitation, aggression, or other aberrant behavior that is interfering with function and quality of life, as determined by their psychiatric interview
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06333041
Study of Cannabidiol in Sanfilippo Syndrome
Phase 2 and 3
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
About 35 people
Started Apr 1, 2026
In plain words A Phase 2 and 3 study of cannabidiol in people 4 and older, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. It plans to enroll about 35 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 4 and older. Conditions: Sanfilippo Syndrome; Mucopolysaccharidosis III.
MPS III diagnosis confirmed by genetic testing
≥ 4 years of age
Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 16 years of age, assent must also be provided when cognitively possible.
If taking any of the following, no dose changes for the last 8 weeks:
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Epidiolex; Placebo
Registered summary
The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome. Each participant's caregiver will be asked to complete surveys related to the participant's behavior, mood, sleep, stooling, pain, and caregiver stress intermittently throughout the study. All participants will be enrolled into one of two cohorts based on enrollment order: 1. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06414473
CBD for Knee Osteoarthritis
Phase 1 and 2
University of Florida
About 30 people
Started Jun 14, 2024
In plain words A Phase 1 and 2 study of cannabidiol in people 40 to 75, run by University of Florida. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75. Conditions: Osteoarthritis, Knee.
established clinical diagnosis of knee osteoarthritis (KOA)
moderate to severe knee pain (≥4/10) with physical activity in one or both knees
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol (CBD) Extract; Placebo
Registered summary
Osteoarthritis is a disease that affects millions of Americans and is the leading cause of persistent pain and physical disability in the older adult population. Many physically active Americans have reported pain-relieving effects of cannabidiol (CBD) that can reduce or eliminate use of nonsteroidal anti-inflammatory drugs (NSAIDs) for activity-related pain with minimal to no side effects. Long-term use of over-the-counter medications, including NSAIDs, can pose a significant health risk, and therefore clinical research on the safety and efficacy of CBD is needed.
Where, as registered
1 US site in 1 state.
RecruitingNCT07167446
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Early phase 1
Fox Chase Cancer Center
About 30 people
Started Oct 14, 2025
In plain words An early phase 1 study of cannabidiol in people 18 and older, run by Fox Chase Cancer Center. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients; Metastatic Colorectal Cancer (CRC); Peripheral Neuropathy Due to Chemotherapy.
Patients with metastatic, locally advanced unresectable colorectal cancer patients planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned).
Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.
ECOG PS 0-2
No prior platinum exposure
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol (CBD); oxaliplatin-based chemotherapy
Registered summary
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
Where, as registered
1 US site in 1 state.
RecruitingNCT05457465
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Phase 2
Mclean Hospital
About 25 people
Started Jun 1, 2023
In plain words A Phase 2 study of cannabidiol in people 18 to 65, run by Mclean Hospital. It plans to enroll about 25 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Bipolar Disorder.
Provides informed consent
Between the ages of 18-65
Fluent in English
Meets DSM-5 criteria for bipolar disorder (type I or II)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol
Registered summary
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
Where, as registered
1 US site in 1 state.
RecruitingNCT06692933
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
Early phase 1
Washington State University
About 24 people
Started Jun 20, 2024
In plain words An early phase 1 study of cannabidiol in people 21 to 64, run by Washington State University. It plans to enroll about 24 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 64; healthy volunteers accepted. Conditions: Interaction.
21-64 years old and healthy;
Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Have taken hemp or cannabis (in any form) before and tolerated it well;
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol in the form of hemp; Clopidogrel
Registered summary
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Where, as registered
1 US site in 1 state.
RecruitingNCT07434895
Repeated CBD Administration and Cannabis Outcomes
Early phase 1
Hannah Harris
About 23 people
Started Aug 5, 2026
In plain words An early phase 1 study of cannabidiol in people 18 to 55, run by Hannah Harris. It plans to enroll about 23 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 55; healthy volunteers accepted. Conditions: Cannabis; Abuse Liability; Experimental Pain in Healthy Human Participants.
English-speaking, literate adults,
Male or female,
Between the ages of 18-55,
Body Mass Index from 18.5-32.0 kg/m2,
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol, Medium Dose; Cannabidiol, Higher Dose; Active Inhaled Cannabis; Placebo Cannabidiol; Placebo Inhaled Cannabis
Registered summary
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Where, as registered
1 US site in 1 state.
RecruitingNCT07298408
Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
Phase 1 and 2
Florida A&M University
About 20 people
Starts Apr 2, 2026 (estimated)
In plain words A Phase 1 and 2 study of cannabidiol in people 40 to 70, run by Florida A&M University. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70. Conditions: Diabetic Peripheral Neuropathic Pain (DPN); Diabetic Neuropathies.
Adult aged 40 to 70 years
Diagnosis of Type 2 Diabetes
Ambulatory and independently living adult
Minimum body weight of 50 kg (to ensure daily dose ≤2 mg/kg)
7 more inclusion criteria and the exclusion criteria are on the listing.
The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07778810
Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome
Phase 2
Johns Hopkins University
About 10 people
Started Sep 17, 2026
In plain words A Phase 2 study of cannabidiol in people 1 month to 18 months, run by Johns Hopkins University. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 1 month to 18 months. Conditions: Sturge - Weber Syndrome (SWS).
Clinical diagnosis of Sturge-Weber Syndrome.
Age 1 to 18 months of age, inclusive.
Neuroimaging demonstrating involvement of 3 or more lobes, or bilateral involvement.
No history of seizures.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Epidiolex 100 mg/mL Oral Solution
Registered summary
Patients with Sturge-Weber syndrome (SWS) are frequently affected by seizures, and seizures are associated with poorer neurological outcomes. To date there is no established means of predicting or preventing seizure onset. Cannabidiol (Epidiolex) was well tolerated in an open label study in this population. This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological outcome.
Where, as registered
1 US site in 1 state.
RecruitingNCT05867849
Cannabidiol for Bipolar Depression (CBD-BD)
Phase 3
University of British Columbia
About 360 people
Started Oct 15, 2023
In plain words A Phase 3 study of cannabidiol in people 19 to 70, run by University of British Columbia. It plans to enroll about 360 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 70. Conditions: Bipolar Disorder.
Males or females aged 19 to 70 years (inclusive).
DSM-5 diagnosis of BD I or BD II, AND a current major depressive episode confirmed by MINI 7.0.2 .
All patients must be taking either a mood stabilizer (i.e. lithium or valproate; lamotrigine monotherapy as a mood stabilizer is acceptable for BD II patients only and not for BD I) OR an atypical antipsychotic OR a combination of these…
Have received a minimum of 6-weeks treatment at adequate doses for treatment of current depressive episode with at least one CANMAT recommended first-line treatment for bipolar I disorder (i.e.
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
Bipolar disorder (BD) is a lifelong condition characterized by recurrent episodes of depression and (hypo)mania. Periods of chronic and recurring depressive episodes are more common and can be severely disabling. Effective treatments exist; however, a significant portion of bipolar depressed patients do not respond to or have difficulty tolerating many of these interventions and thus look beyond established treatments to achieve symptom relief. The full summary is on the listing.
Where, as registered
No US site; Canada (6).
RecruitingNCT06448923
Cannabidiol After Multi-Trauma for Pain and Opioid Therapy
Phase 2
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
About 225 people
Started Jun 1, 2025
In plain words A Phase 2 study of cannabidiol in people 18 to 70, run by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. It plans to enroll about 225 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Fracture.
Patients with a long bone fracture of the lower limb (tibia, fibula, femur, metatarsals, and phalanges) or the upper limb (humerus, radius, ulna, metacarpals, and phalanges) treated to Sacre-Coeur Hospital in Montreal (HSCM) within one…
Participants is between 18 and 70 years of age
Patients with or without surgical procedures
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Cannabidiol; Placebo
Registered summary
The aim of this project is to investigate the therapeutic potential and safety of acute Cannabidiol (CBD) treatment on longitudinal pain symptoms, and to assess potential interactions with pain mediators including opioids and sex on CBD treatment response. To this end, this research protocol proposes a comprehensive translational approach including a placebo-controlled randomized clinical trial comparing two daily doses of CBD treatment administered for one month on pain relief. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06845124
A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence
Phase 2
Central Institute of Mental Health, Mannheim
About 150 people
Started Jul 22, 2025
In plain words A Phase 2 study of cannabidiol in people 18 to 70, run by Central Institute of Mental Health, Mannheim. It plans to enroll about 150 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Alcohol Addiction; Alcoholism.
Age between 18 and 70 years
Patients meeting the diagnosis of an alcohol dependence according to the ICD-10
Patients reporting alcohol craving as symptom of AD according to the ICD10 symptom definition
Ability of subject to understand character and individual consequences of the clinical trial
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol capsules; Naltrexone (drug); Placebo
Registered summary
Alcohol addiction (AD) is a chronic relapsing disorder with currently limited pharmacological treatment options. Alcohol craving, a hallmark symptom of AD that drives relapse in patients, is only insufficiently treated by existing medication. One promising new compound for the treatment of alcohol craving in AD is Cannabidiol (CBD), which showed beneficial effects on alcohol craving in preliminary clinical studies. The full summary is on the listing.
Where, as registered
No US site; Germany (2).
RecruitingNCT06629389
Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms
Phase 2
Laboratorio Elea Phoenix S.A.
About 88 people
Started Nov 28, 2024
In plain words A Phase 2 study of cannabidiol in people 40 to 80, run by Laboratorio Elea Phoenix S.A.. It plans to enroll about 88 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 80. Conditions: Parkinson Disease.
Participants between 40 and 80 years old.
Participants diagnosed with PD according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson\'s disease (72), and to the Brain Bank Criteria for Parkinson\'s disease, with mild to moderate disease as measured by…
Participants who have not changed their anti-Parkinson's drugs (or dose) at least one month prior to study entry.
Acceptance by the participant by signing the ICF.
1 more inclusion criterion and the exclusion criteria are on the listing.
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.
Where, as registered
No US site; Argentina (1).
RecruitingNCT07549256
Cannabidiol for Pain Relief of Patients With End-stage mCRPC
Phase 2
Regionshospital Nordjylland
About 58 people
Started Jun 12, 2026
In plain words A Phase 2 study of cannabidiol in male participants of any age, run by Regionshospital Nordjylland. It plans to enroll about 58 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants of any age. Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC).
Patients diagnosed with mCRPC as documented by increasing PSA despite optimally attempted treatment, and no other therapeutic options.
Treatment-resistance or ineligible to standardized cancer therapy, incl. medical and surgical castration, chemotherapy, and super hormone treatment.
Minimum 3 months since radiation therapy, if part of treatment.
Opioid-requiring pain
The exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol; Placebo
Registered summary
The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC). The primary objective is to determine whether cannabidiol (CBD) treatment can reduce the need for opioids in patients with end-stage mCRPC. Additionally, the study will assess a range of clinical endpoints in patients with end-stage mCRPC, including: 1. The efficacy of CBD treatment in alleviating pain 2. The efficacy of CBD treatment in reducing the need for non-opioid medications and concomitant therapies 3. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT07271030
The Use of Cannabidiol Suppositories for Sexual Pain
No phase
London Metropolitan University
About 50 people
Started Jan 16, 2026
In plain words A study of cannabidiol in people 18 to 100, run by London Metropolitan University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 100; healthy volunteers accepted. Conditions: Well-Being, Psychological; Quality of Life; Sexual Behavior; Sexual Pain Disorder.
Has previously used cannabidiol in any capacity and has not experienced any allergic reaction
Is experiencing sexual pain
There will be an absence of co occurring difficulties
Has attempted sexual intercourse in the last month
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabidiol suppository intervention 1; Cannabidiol suppository intervention 2; Cannabidiol suppository intervention 3; Non cannabidiol group control
Registered summary
Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life. Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services. A brief overview of the intervention: Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The full summary is on the listing.